Nanoscience Inc., the specialist niche investor in emerging technologies with strong commercial propositions from within the growing nanotechnology sector, is pleased to announce that its wholly owned subsidiary, Toumaz Technology Limited has been granted its core patent surrounding the AMx (Advanced Mixed Signal) technology in the key jurisdiction of Australia.
Copernicus Therapeutics, Inc. announced today that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT and Copernicus to develop gene therapy to treat cystic fibrosis.
Universal Capital Management, Inc., a publicly traded venture capital company that provides emerging growth companies with management and strategic resources for successful growth, acknowledged the Form 8-K filed by Third-Order Nanotechnologies, Inc. on December 7, 2007, one of Universal Capital's largest portfolio companies.
Nanogen, Inc., developer of advanced diagnostic products, announced that it has filed with the Securities and Exchange Commission a preliminary proxy statement for a special meeting of its stockholders.
AMAG Pharmaceuticals, Inc. today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc. will present an overview of the Company at the 26th Annual JPMorgan Healthcare Conference at 11:00 a.m. PT on Tuesday, January 8, 2008.
Nanogen, Inc., developer of advanced diagnostic products, announced today that it has delivered the second phase milestone requirements, including the point-of-care prototype device to detect influenza viruses rapidly in clinical samples, to the Center for Disease Control and Prevention for their evaluation.
Luna Innovations Incorporated has been awarded a grant from the National Heart, Lung, and Blood Institute to develop a new diagnostic agent that could improve the diagnosis of coronary artery disease, a condition that causes most heart attacks.
Valutek, a leading solutions provider of products for cleanrooms and controlled environments, has made a $10,000 product donation to the Translational Genomics Research Institute. The contribution actively supports Phoenix's burgeoning biotech movement and directly benefits TGen's research initiatives.